Fanconi Anemia, Complementation Group D2 (FANCD2) antibody (HRP)

Details for Product No. ABIN250521
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms FA4, FAD, FACD, FA-D2, FANCD, AU015151, BB137857, 2410150O07Rik, FAD2, FANCD2, CG17269, CG31192, CG31194, Dmel\\CG17269, dmFANCD2, xfancd2
Reactivity
Human
(91), (53), (44), (36), (24), (24), (3)
Host
Rabbit
(80), (17)
Clonality
Polyclonal
Conjugate
HRP
(4), (4), (3), (3), (3), (3), (3), (3), (3), (3), (3), (1), (1), (1)
Application
Immunofluorescence (IF), Immunoprecipitation (IP), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
(62), (31), (30), (30), (23), (15), (10), (2), (1), (1), (1), (1)
Pubmed 15 references available
Catalog no. ABIN250521
Quantity 50 µL
Price
Contact our Customer Service for availability and price in your country.
Shipping to United States (Change)
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Human FANCD2 fusion protein (N-terminal fragment).
Specificity This antibody is specific for FANCD2. Species Reactivity: ABIN151329 reacts with human and mouse FANCD2.
Cross-Reactivity Human, Mouse (Murine)
Alternative Name FANCD2
Background Fanconi anemia (FANC) is a human autosomal-recessive cancer susceptibility disordercharacterized by congenital defects, progressive bone marrow failure, and cellularhypersensitivity to mitomycin C (MMC). The FANC subunit D2 protein is vital for cellularresistance to DNA cross-linking and the arrest of DNA synthesis after ionizing radiation. DNA damage activates the monoubiquitination of FANCD2, targeting nuclear focicontaining the BRCA1 protein. Alternate Names: anti-FA4 antibody, anti-FACD antibody, anti-FAD antibody, anti-FAD2 antibody,anti-FANCD antibody, anti-Fanconi Anemia Complementation Group D antibody,anti-Fanconi Pancytopenia Type 4 antibody.
Gene ID 2177, 211651
UniProt Q9BXW9
Research Area Chromatin and Nuclear Signaling, DNA/RNA
Application Notes Suggested working dilutions: immunohistochemistry 2.5-5.0 ug/ml,immunofluorescence 1:200-1:500,Western Blot 1:10000-1:20000
Restrictions For Research Use only
Format Liquid
Buffer PBS with 1% BSA. Preservative: No Preservative.
Storage 4 °C
Supplier Images
anti-Fanconi Anemia, Complementation Group D2 (FANCD2) antibody (HRP) FancD2 colocalizes in vivo with another protein in SiHa cells after cell exposure to IR. Proliferating SiHa cells were exposed to 10 Gy of IR and double -color immunofluorescence staining was performed after 8 h. Images were captured in a Kodak digital image system on a Leica fluorescence microscope.
anti-Fanconi Anemia, Complementation Group D2 (FANCD2) antibody (HRP) (2) FancD2 colocalizes in vivo with another protein in U2OS cells after cell exposure to IR. Proliferating U2OS cells were exposed to 10 Gy of IR and double -color immunofluorescence staining was performed after 8 h. Images were captured in a Kodak digital image system on a Leica fluorescence microscope.
anti-Fanconi Anemia, Complementation Group D2 (FANCD2) antibody (HRP) (3) FANCD2 in HeLa WCE using ABIN151329 (lot C).
General Garcia-Higuera, Taniguchi, Ganesan et al.: "Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway." in: Molecular cell, Vol. 7, Issue 2, pp. 249-62, 2001 (PubMed).

McMahon, Sangerman, Goodman et al.: "Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand cross-links." in: Biochemistry, Vol. 40, Issue 24, pp. 7025-34, 2001 (PubMed).

Digweed, Rothe, Demuth et al.: "Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia." in: Carcinogenesis, Vol. 23, Issue 7, pp. 1121-6, 2002 (PubMed).

Taniguchi, Garcia-Higuera, Andreassen et al.: "S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51." in: Blood, Vol. 100, Issue 7, pp. 2414-20, 2002 (PubMed).

Sridharan, Brown, Lambert et al.: "Nonerythroid alphaII spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links." in: Journal of cell science, Vol. 116, Issue Pt 5, pp. 823-35, 2003 (PubMed).

Lensch, Tischkowitz, Christianson et al.: "Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia." in: Blood, Vol. 102, Issue 1, pp. 7-16, 2003 (PubMed).

Taniguchi, Tischkowitz, Ameziane et al.: "Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors." in: Nature medicine, Vol. 9, Issue 5, pp. 568-74, 2003 (PubMed).

Olopade, Wei: "FANCF methylation contributes to chemoselectivity in ovarian cancer." in: Cancer cell, Vol. 3, Issue 5, pp. 417-20, 2003 (PubMed).

Rothfuss, Grompe: "Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway." in: Molecular and cellular biology, Vol. 24, Issue 1, pp. 123-34, 2003 (PubMed).

Donahue, Campbell: "A Rad50-dependent pathway of DNA repair is deficient in Fanconi anemia fibroblasts." in: Nucleic acids research, Vol. 32, Issue 10, pp. 3248-57, 2004 (PubMed).

Bekker-Jensen, Lukas, Kitagawa et al.: "Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks." in: The Journal of cell biology, Vol. 173, Issue 2, pp. 195-206, 2006 (PubMed).

Mukhopadhyay, Leung, Hicks et al.: "Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia." in: The Journal of cell biology, Vol. 175, Issue 2, pp. 225-35, 2006 (PubMed).

Dunn, Potter, Rees et al.: "Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light." in: Cancer research, Vol. 66, Issue 23, pp. 11140-7, 2006 (PubMed).

Oda, Hayano, Miyaso et al.: "Hsp90 regulates the Fanconi anemia DNA damage response pathway." in: Blood, Vol. 109, Issue 11, pp. 5016-26, 2007 (PubMed).

Jacquemont, Taniguchi: "Proteasome function is required for DNA damage response and fanconi anemia pathway activation." in: Cancer research, Vol. 67, Issue 15, pp. 7395-405, 2007 (PubMed).

Hosts (80), (17)
Reactivities (91), (53), (44), (36), (24), (24), (3)
Applications (62), (31), (30), (30), (23), (15), (10), (2), (1), (1), (1), (1)
Conjugates (4), (4), (3), (3), (3), (3), (3), (3), (3), (3), (3), (1), (1), (1)
Epitopes (23), (12), (9), (2), (2), (1), (1), (1)
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Validation Images
back to top